IL-17, IL-23 and IL-12/23 biologics on every 2026 Connecticut Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 11 stand-alone Part D plans in Connecticut cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
11 plans, cheapest premium first. Scroll sideways for all of them →
| Drug | Humana Basic Rx Plan$8.40/moS5884-102 | Wellcare Value Script$16.40/moS4802-137 | Blue MedicareRx Value Plus$20.70/moS2893-001 | Wellcare Classic$21.70/moS4802-076 | SilverScript Choice$32.70/moS5601-004 | AARP Medicare Rx Saver from UHC$38.70/moS5921-348 | Humana Value Rx Plan$73.60/moS5884-182 | Humana Premier Rx Plan$138.60/moS5884-149 | HealthSpring Assurance Rx$139.30/moS5617-008 | AARP Medicare Rx Preferred from UHC$155.10/moS5921-385 | Blue MedicareRx Premier$238.60/moS2893-003 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stelaraustekinumab | Tier 5PA25%QL 1.5/84d | Not covered | Tier 5PA25%QL 0.5/28d | Not covered | Tier 5PA25%QL 0.5/28d | Not covered | Tier 5PA26%QL 1.5/84d | Tier 5PA33%QL 1.5/84d | Tier 5PA25%QL 0.5/28d | Not covered | Tier 5PA33%QL 0.5/28d |
| ustekinumab biosimilarsWezlana, Selarsdi, Pyzchiva and others | Tier 5PA25%QL 1.5/84d | Not covered | Tier 5PA25%QL 0.5/28d | Not covered | Tier 5PA25%QL 0.5/28d | Not covered | Tier 5PA26%QL 1.5/84d | Tier 5PA33%QL 1.5/84d | Tier 5PA25%QL 0.5/28d | Not covered | Tier 5PA33%QL 0.5/28d |
| Wezlanaustekinumab-auub | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Selarsdiustekinumab-aekn | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Tier 3PA21%QL 0.5/28d | Not covered | Not covered |
| Skyrizirisankizumab | Tier 5PA25%QL 2/84d | Tier 5PA25%QL 6/365d | Tier 5PA25%QL 6/365d | Tier 5PA25%QL 6/365d | Tier 5PA25%QL 6/365d | Tier 5PA25%QL 1/28d | Tier 5PA26%QL 2/84d | Tier 5PA33%QL 2/84d | Tier 5PA25%QL 2/28d | Tier 5PA31%QL 1/28d | Tier 5PA33%QL 6/365d |
| Tremfyaguselkumab | Tier 5PA25%QL 3/84d | Tier 5PA25%QL 2/28d | Tier 5PA25%QL 1/28d | Tier 5PA25%QL 2/28d | Tier 5PA25%QL 1/28d | Tier 5PA25% | Tier 5PA26%QL 3/84d | Tier 5PA33%QL 3/84d | Tier 5PA25%QL 2/28d | Tier 5PA31% | Tier 5PA33%QL 1/28d |
| Cosentyxsecukinumab | Tier 5PA25%QL 8/28d | Tier 5PA25%QL 10/28d | Not covered | Tier 5PA25%QL 10/28d | Not covered | Tier 5PA25%QL 10/30d | Tier 5PA26%QL 8/28d | Tier 5PA33%QL 8/28d | Tier 5PA25%QL 10/28d | Tier 5PA31%QL 10/30d | Not covered |
| Taltzixekizumab | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| Bimzelxbimekizumab | Not covered | Not covered | Tier 5PA25%QL 2/28d | Not covered | Tier 5PA25%QL 4/28d | Not covered | Not covered | Not covered | Not covered | Not covered | Tier 5PA33%QL 2/28d |
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.